The Liver Meeting 2022-Cholestatic & Autoimmune Liver Diseases SIG and Liver Transplant & Surgery SIG Program: Optimizing Pre- and Post-Transplant Management of Immune Mediated Liver Disease. PART 1: Pre-Transplant Management of Immune Mediated Liver Disease

Cholestatic & Autoimmune Liver Diseases SIG and Liver Transplant & Surgery SIG Program: Optimizing Pre- and Post-Transplant Management of Immune Mediated Liver Disease. PART 1: Pre-Transplant Management of Immune Mediated Liver Disease

Back to course

Video Transcription

Video Summary

The video transcript discusses the evolving epidemiology and disparities in listing and transplantation in patients with autoimmune liver disease, particularly autoimmune hepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). It emphasizes the limited data available, with much of it coming from European populations. The rates of autoimmune liver disease, particularly autoimmune hepatitis, are rising and vary based on geography, risk factors, and demographics.<br /><br />Disparities in listing and transplantation are noted, particularly for African Americans and Hispanics who have higher waitlist mortality and lower access to transplantation. Disparities are also seen based on age, gender, and payment source. Access to transplantation for autoimmune liver disease is generally lower compared to other liver diseases.<br /><br />The video also discusses the diagnosis and management of dominant strictures and cholangiocarcinoma in PSC. Dominant strictures have a worse prognosis and an increased risk of cholangiocarcinoma. The diagnostic challenge lies in differentiating it from other benign and malignant conditions due to limitations in current biopsy techniques.<br /><br />Overall, the video highlights the need for further research and understanding of the epidemiology, disparities, and management of autoimmune liver disease and associated complications. It also touches on the diagnostic methods and treatment options for PSC and emphasizes the importance of ruling out cholangiocarcinoma.

Asset Caption

Examine the evolving epidemiology, pre- and posttransplant management of immune mediated liver diseases and their complications by integrating current evidence-based practice in pre-transplant clinical care, advances in diagnostic and management techniques, and state-of-the-art management.

Keywords

epidemiology

disparities

listing

transplantation

autoimmune liver disease

autoimmune hepatitis

primary biliary cholangitis

primary sclerosing cholangitis

African Americans

Hispanics

diagnosis

management

Ska Reggae